Prevalence of anemia in patients admitted to hospital with a primary diagnosis of congestive heart failure-Reference-Cited by-同舟云学术

Prevalence of anemia in patients admitted to hospital with a primary diagnosis of congestive heart failure

Published:2004-07 Issue:1 Volume:96 Page:79-87
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Wexler Dov,Silverberg Donald,Sheps David,Blum Miriam,Keren Gad,Iaina Adrian,Schwartz Doron

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference55 articles.

1. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalization;Silverberg;J. Am. Coll. Cardiol.,2000

2. The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and renal failure and markedly reduces hospitalization;Silverberg;Clin. Nephrol.,2002

3. The effect of correction of anemia in diabetic and non diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron;Silverberg;Nephrol. Dial. Transplant.,2003

4. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study;Silverberg;J. Am. Coll. Cardiol.,2001

5. Epidemiology and prevention of cardiac failure: Framingham study insights;Kannel;Eur. Heart J.,1987

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacoeconomic analysis of ferric carboxymaltose in patients with chronic heart failure and iron deficiency in the Russian Federation;Glavvrač (Chief Medical Officer);2022-06-14

2. Acute heart failure and iron deficiency: a prospective, multicentre, observational study;ESC Heart Failure;2021-12-04

3. Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost‐effectiveness analysis utilising AFFIRM‐AHF;European Journal of Heart Failure;2021-06-30

4. Anemia and Management of Heart Failure Patients;Heart Failure Clinics;2021-04

5. Rationale and design of the AFFIRM‐AHF trial: a randomised, double‐blind, placebo‐controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron‐deficient patients admitted for acute heart failure;European Journal of Heart Failure;2019-12